Miquel Tarón
323 works · 19,362 citations · h-index 54
Top works
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
- Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.
- Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations
- Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients
- Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer
- Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients
- Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial.
- FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR
- Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop
- A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells
- The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR -Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial
- Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non–Small-Cell Lung Cancer
- Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy
- Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer
- BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer
- Single nucleotide polymorphisms and outcome in docetaxel–cisplatin-treated advanced non-small-cell lung cancer
- Circulating MicroRNA Signatures of Tumor-Derived Exosomes for Early Diagnosis of Non–Small-Cell Lung Cancer
- DNA repair and cisplatin resistance in non-small-cell lung cancer